This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Can Danaher's Diagnostics Unit Sustain Growth Amid Lower Sales in China?
by Zacks Equity Research
DHR's Diagnostics unit posts steady Q2 growth, led by Beckman Coulter demand, while China headwinds weigh on results.
Danaher's Life Sciences Segment Shrinks: What's the Path Forward?
by Zacks Equity Research
DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
by Moumi Mondal
HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
by Zacks Equity Research
DHR's Biotechnology unit grows 6% in Q2, driven by bioprocessing, despite weakness in research equipment demand.
Danaher Gains From Business Strength Amid Persisting Headwinds
by Zacks Equity Research
DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.
Why Is Teladoc (TDOC) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
by Moumi Mondal
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Markel's Q2 Earnings Surpass Estimates, Premiums Rise Y/Y
by Zacks Equity Research
MKL tops Q2 earnings and revenue estimates, but profits dip as rising expenses weigh on margins.
International Markets and Danaher (DHR): A Deep Dive for Investors
by Zacks Equity Research
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Here's Why Danaher (DHR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of +9.76% and +1.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Danaher (DHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Danaher (DHR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Analyst Reports for Eli Lilly, Home Depot & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?